< Home < Back

Biocon informs about company statement

Date: 29-07-2026
Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen’. The above information will also be available on the website of the Company at www.biocon.com. 

The above information is a part of company’s filings submitted to BSE.